Antihypertensive therapy and new onset diabetes

Journal of Hypertension

Volumn 22, Issue 10, 2004, Pages 1845-1847

  Messerli, Franz H ^a   Grossman, Ehud ^b   Leonetti, Gastone ^c  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LISINOPRIL; THIAZIDE DIURETIC AGENT; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETES MELLITUS; EDITORIAL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT;

EID: 5044223690     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200410000-00001     Document Type: Editorial

References (29)

1. Getting a handle on obesity (editorial). Lancet 2002; 359:1955.
2. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003; 139:802-809.
3. Greenlund KJ, Zheng ZJ, Keenan NL, Giles WH, Casper ML, Mensah GA, et al. Trends in self-reported multiple cardiovascular disease risk factors among adults in the United States, 1991-1999. Arch Intern Med 2004; 164:181-188.
4. Lewis PJ, Kohner EM, Petrie A, Dollery CT. Deterioration of glucose tolerance in hypertensive patients on prolonged diuretic treatment. Lancet 1976; 1:564-566.
5. Murphy MB, Lewis PJ, Kohner E, Schumer B, Dollery CT. Glucose intolerance in hypertensive patients treated with diuretics; a 14-year follow-up. Lancet 1982; 2:1293-1295.
6. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 1999; 353:611-616.
7. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B, et al., for the STOP-Hypertension-2 study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertensinon-2 study. Lancet 1999; 354:1751-1756.
8. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
9. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, et al., for the HOPE Study Investigators. Ramipril and the development of diabetes. JAMA 2001; 286:1882-1885.
10. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al., for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-592.
11. Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T, et al. Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in intervention as a goal in hypertension (INSlGHT). Hypertension 2003; 41:431-436.
12. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al., for the INVEST Investigators. A calcium antagonist versus a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trando-lapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805-2816.
13. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356:359-365.
14. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beefers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:1004-1010.
15. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al., for the SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21:875-886.
16. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al., for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362:772-776.
17. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21:1563-1574.
18. Opie LH: Old antihypertensives and new diabetes. J Hypertens 2004; 22:1453-1458.
19. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031.
20. Conn JW. Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med 1965; 273:1135-1143.
21. Fajans SS, Floyd JC Jr, Knopf RF, Rull J, Guntsche EM, Conn JW. Benzothiadiazine suppression of insulin release from normal and abnormal islet tissue in man. J Clin Invest 1966; 45:481-492.
22. Helderman JH, Elahi D, Andersen DK, Raizes GS, Tobin JD, Shocken D, Andres R. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1983; 32:106-111.
23. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289:2560-2571.
24. Messerli FH. ALLHAT, or the soft science of the secondary end point. Ann Intern Med 2003; 139:777-780.
25. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio, Filippucci L, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43:963-969.
26. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999; 33:1130-1134.
27. Eberly LE, Cohen JD, Prineas R, Yang L. Intervention trial research group. Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the multiple risk factor intervention trial experience. Diabetes Care 2003; 26:848-854.
28. Shamiss A, Carrol J, Peleg E, Grossman E, Rosenthal T. Enalapril with and without hydrochlorothiazide: effects on insulin sensitivity and metabolic abnormalities of NIDDM hypertensive patients. Am J Hypertens 1995; 8:276-281.
29. POEM*: diuretics should be first line treatment for hypertension. BMJ 2003; 327: d0i:10.1136/bmj.327.7413.0-e.